Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 12/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 3/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215890 | 0.83 | GPR52 (0.49) | GPR52 | |
| SCHEMBL3208716 | 0.82 | RAD52 (0.41) | GPR52CDK8RAD52PAX8ALDH1A1 | |
| SCHEMBL1856214 | 0.81 | GPR52 (0.50) | GPR52CDK8 | |
| SCHEMBL1852034 | 0.79 | MAPT (0.43) | GPR52ALDH1A1 | |
| SCHEMBL1846506 | 0.75 | GPR52 (0.81) | GPR52CDK8ALDH1A1POLB | |
| SCHEMBL3198028 | 0.75 | GPR52 (0.53) | GPR52CDK8ALDH1A1POLB | |
| SCHEMBL1854536 | 0.74 | GPR52 (0.57) | GPR52CDK8ALDH1A1POLB | |
| SCHEMBL1853913 | 0.74 | GPR52 (0.62) | GPR52CDK8 | |
| SCHEMBL1852406 | 0.74 | GPR52 (0.66) | GPR52CDK8 | |
| SCHEMBL1850688 | 0.74 | GPR52 (0.81) | GPR52CDK8ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885CDK8 3401/4885RAD52 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.